Our findings revealed that the proportion of tumor-infiltrating NK cells was significantly increased following combination therapy in both the LUAD and LUSC humanized mouse models compared with that in the monotherapy, suggesting that the combination of PD-1 inhibitor with SMI recruited NK cells into the TME of NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.